Citadel Advisors
JUNO

Citadel Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Citadel Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-58,900
Closed -$2.69M – 9173
2017
Q4 		$2.69M Sell
58,900
-15,300
-21% -$763K ﹤0.01% 3235
2017
Q3 		$3.33M Buy
74,200
+17,900
+32% +$610K ﹤0.01% 2770
2017
Q2 		$1.68M Buy
56,300
+21,100
+60% +$521K ﹤0.01% 3397
2017
Q1 		$781K Sell
35,200
-19,400
-36% -$416K ﹤0.01% 4367
2016
Q4 		$1.03M Sell
54,600
-2,000
-4% -$48.9K ﹤0.01% 3819
2016
Q3 		$1.7M Buy
56,600
+19,100
+51% +$594K ﹤0.01% 3166
2016
Q2 		$1.44M Buy
37,500
+300
+0.8% +$12.5K ﹤0.01% 3114
2016
Q1 		$1.42M Buy
37,200
+21,300
+134% +$742K ﹤0.01% 3051
2015
Q4 		$699K Sell
15,900
-26,800
-63% -$1.33M ﹤0.01% 4043
2015
Q3 		$1.74M Buy
42,700
+26,800
+169% +$1.18M ﹤0.01% 3125
2015
Q2 		$848K Sell
15,900
-8,500
-35% -$451K ﹤0.01% 4195
2015
Q1 		$1.48M Buy
+24,400
New +$1.18M ﹤0.01% 3454

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Citadel Advisors's JUNO Position: Q1 2018 in Review

Citadel Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 224,352 shares — an estimated $10.3M sold.

Citadel Advisors first reported a position in JUNO in Q4 2014 and held it in 11 quarters. The position peaked at $19.1M in Q2 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Citadel Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Citadel Advisors sold 224,352 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $10.3M.
  • Citadel Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 11 quarters.
  • Citadel Advisors's Juno Therapeutics, Inc. position peaked at $19.1M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.